Prospective, longitudinal data with a contemporaneous non-cancer cohort has enable us to make important novel observations in regard to cancer patients on treatment & admitted with COVID Lance Turtle ⬇️ this demonstrates power of national pandemic planning ISARIC ISARIC4C

All places funded for women & men living with secondary breast cancer to attend this first of a kind event, & availability to watch online. Grateful to Lesley Stephen Make 2nds Count real team effort to make this happen. Very grateful to our funders for their support.

Delighted that first national conference in the UK for patients living with secondary BC will be happening in Liverpool, 9th-11th July 2024. Hope to make this a regular event. Limited places details👇⁦Make 2nds Count⁩ ⁦⁦Lesley Stephen⁩ make2ndscount.co.uk/support/commun…

Keynote 522 Annals of Oncology Pembro vs placebo early TNBC. EFS by RCB, med. FU 39 mths. 🔵Largest benefit for pembro observed with RCB-2.🔵50% of distant recurrences are brain mets in RCB 0/1. CNS appears a sanctuary site & predicting, preventing & detecting early seems key.

Just out, our paper demonstrating the clinical activity of a Selective Androgen Receptor Modulator. Important as shows in ER+/HER2- BC you can get clinical activity without directly targeting ER. This is about ‘nudging & budging’ ER not ‘bashing & smashing’ it. Important paper.

It’s #WorldCancerDay 2024 & 🏴󠁧󠁢󠁥󠁮󠁧󠁿 doesn’t have a National Cancer Plan. This not for want of a vision ⬇️ Ajay Aggarwal Nicola Fearnhead
Anna Kirby Mark Lawler Sarah Quinlan Carlo Palmieri Tom Roques Richard Simcock Fiona Walter Professor Pat Price Richard Sullivan The Lancet Oncology The Royal College of Radiologists

Complexly novel way to assess risk of recurrence in ER+/HER2- early breast cancer using mid-infrared spectrometer digistain It’s simple,quick & can be done locally. First data using Nottinghan series, shows it can separate patients into low vs high risk. More studies underway.

ELAINE2 study: Lasofoxifene (SERM) + abemaciclib in ESRmut MBC (97% prior CDK4/6 exposed). Median PFS: 56 wks (95% CI 31.9- NE); ORR: 55.6% (95% CI 33.7% to 75.4%). Well tolerated predominantly grade1/2 diarrhea, nausea, fatigue & vomiting. Small study but very exciting data.

Discussion paper from IPPR on reforming health & care services so that they work both for public health and public finances. A prevention & productivity shift are key, as well as ending the feast & famine funding model.

Check up on your friends who you didn't send Christmas cards: those who are depressed are less likely to send Christmas cards, especially Christians who are depressed, finds Stephen Gallagher Siobhán Howard Jennifer McMahon 🌻 Carlo Palmieri doi.org/10.1080/233119…

MONARCH-3 and that non-significant p-value. Useful discussion in ‘view from the trenches’ session #SABCS2023

DEBBRAH Study: Cohort 5: T-Dxd Rx for HER2 low or HER2+ leptomeningeal disease (CSF+). Small numbers as is the way with LMD studies but promising activity. Larger cohorts needed. LMD is a focus of BIG-NCTN collaboration, a global & coordinated effort is needed for LMD #SABCS23

KATHERINE Overall survival data
OS ⬆️ 4.7% at 7 years for the use of T-DM1 as compared to Trastuzumab following no pCR to neoadj therapy. #SABCS2023

INAVO120 1st data for triplet therapy of ET, CDK4/6i & PI3Ki in PIK3CA-mutated MBC. Addition of Inavolisib to
Fulvestrant plus Palbociclib significantly increased by 7.7 mths (HR 0.43; 95% CI 0.32, 0.59; p<0.0001). Usual PI3KCAi & CDk4/6i toxicity seen. #SABCS23

TROPION-Breast01: Dato-DXd vs physicians choice. ⬆️PFS favouring Dato-Dxd (Δ 2.4 mths, HR: 0.64; 95% CI 0.53-0.76). Improved QoL also reported. We need more focus & discussion on QoL, what instruments used, what they mean & don’t mean & how we can standardise Lesley Fallowfield

MONARCH 3 Final Overall Survival: No statistical improvement in OS ❌ but OS was improved by median 13 month favouring abemaciclib arm. Data for ribociclib/MONALEESA-2 shown for comparison OS ✔️. #SABCS23

Scottish colleagues & The Royal College of Radiologists request meeting with Chief Medical Officer 🏴󠁧󠁢󠁳󠁣󠁴󠁿 Prof Sir Gregor Smith to discuss SACT workforce crisis. The Royal College of Radiologists Association of Cancer Physicians policy briefing on issue to Office of the Chief Executive NHSScotland Scottish Government 👉🏻 tinyurl.com/32252jrr Policymakers across 🇬🇧 need to listen & act

SACT capacity crisis in NHS The Royal College of Radiologists briefing document. The innovations in cancer care that are happening will be worthless if they don’t get to patients. Lives will be lost. There is both an ethical & economic imperative to act & to act at pace.

The perfect storm of under filling of clinical & medical oncology training places & looming retirements. Data for consultant clinical oncology much more granular via The Royal College of Radiologists Clear action on addressing recruitment gap required Royal College of Physicians Association of Cancer Physicians

It was a pleasure to provide secondary breast cancer charity Make 2nds Count with free advertising space for their hugely impactful #TruthBeTold campaign this month.